hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06263621 id: 855090 briefTitle: Changing Portion Size Descriptions in a Cafeteria overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-11 date: 2024-05-29 date: 2024-05-29 date: 2024-02-16 date: 2024-02-26 name: University of Pennsylvania class: OTHER name: Restaurant Associates briefSummary: The goal of this this intervention is to test the degree to which a portion size labeling intervention influences consumer selection of smaller portions at two large cafés. The main question it aims to answer is: Do consumers order fewer calories when the portion size label for the smaller entree is called "standard" instead of "small"?
Participants will order lunch as usual in the two cafes (one intervention, one control) for 5.5 months, and all order items will be recorded in the check-out system. One cafe will receive the labeling intervention, while the other will not. Researchers will compare the average calories per order between the two cafes to see if there are differences. conditions: Food Selection conditions: Obesity conditions: Weight Gain conditions: Food Preferences studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Entrees are offered in two different portion sizes at two cafes. The cafes were randomized to either receive the "Standard" portion label for the smaller size (Intervention) or the "Small" portion label for the smaller size (Control). The larger portion was labeled "Large." Daily lunch transaction data will be provided by the cafes. primaryPurpose: PREVENTION masking: NONE count: 12000 type: ESTIMATED name: Intervention "Standard" measure: Average kcal per entree sold measure: Number of entrée units purchased measure: Total kcal per transaction measure: Weekly gross sales sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Courtyard Cafe city: Boston state: Massachusetts zip: 02115 country: United States lat: 42.35843 lon: -71.05977 facility: Elements Cafe city: Boston state: Massachusetts zip: 02115 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06263608 id: BUN B3002023000204 briefTitle: Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation acronym: STAROSA overallStatus: RECRUITING date: 2024-02-23 date: 2028-02 date: 2028-02 date: 2024-02-16 date: 2024-03-06 name: University Hospital, Antwerp class: OTHER name: Jessa Hospital name: Hasselt University name: Universiteit Antwerpen briefSummary: The main goal of this prospective pre-post implementation study is to investigate how a structured testing and treatment program for obstructive sleep apnea using the NOX T3s device and a Fitbit smartwatch with the FibriCheck algorithm impacts the proportion of atrial fibrillation (AF) in an AF population.
Participants will wear the NOX T3s respiratory polygraphy device for one night at home. In case of a positive obstructive sleep apnea diagnosis, patients will be referred to the sleep clinic for a polysomnography examination. Patients positively diagnosed with polygraph will be monitored semi-continuously with the Fitbit smartwatch for three months. After the polysomnography examination, the positively diagnosed patients will be monitored semi-continuously for another three months after initiation of treatment (mostly continuous positive airway pressure (CPAP) treatment). Additionally, patients will be administered satisfaction and symptom burden questionnaires twice: right after the polysomnography examination and after the 3-month treatment. conditions: Atrial Fibrillation conditions: Obstructive Sleep Apnea studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 209 type: ESTIMATED name: (Cardio)Respiratory polygraphy (NOX T3s) name: Polysomnography name: Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV) name: Fitbit smartwatch measure: AF burden before and after CPAP treatment measure: Obstructive sleep apnea severity agreement between polygraphy and polysomnography measure: False positive rate of polygraphy measure: Total sleep apnea burden measure: CPAP/BiPAP/ASV compliance measure: Sleep score measure: Patients' AF-related symptom burden, assessed by the Leuven ARrhythmia Questionnaire (LARQ) measure: Patients' obstructive sleep apnea-related symptom burden, assessed by the Berlin Questionnaire (BQ) measure: Patients' obstructive sleep apnea-related symptom burden, assessed by the Epworth Sleepiness Scale (ESS) measure: Polygraphy negative patients measure: User-friendliness of the NOX T3s polygraphy device measure: User-friendliness of the Fitbit-based FibriCheck monitoring measure: Uptake rate of the advice to patients to undergo a polysomnography examination measure: Protocol adherence to smartphone heart rhythm measurements measure: The quality of the FibriCheck measurements measure: Number of technical issues sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital of Antwerp status: RECRUITING city: Edegem country: Belgium name: Lien Desteghe, MSc PhD role: CONTACT email: lien.desteghe@uza.be lat: 51.15662 lon: 4.44504 facility: Jessa Hospital status: RECRUITING city: Hasselt country: Belgium name: Lien Desteghe, MSc PhD role: CONTACT email: lien.desteghe@jessazh.be lat: 50.93106 lon: 5.33781 hasResults: False
nctId: NCT06263595 id: REB23-1754 briefTitle: Semaglutide and Preoperative Residual Gastric Volumes overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-16 date: 2024-02-16 name: University of Calgary class: OTHER name: Alberta Health services briefSummary: Given the pharmacodynamic and pharmacokinetic properties of glucagon-like peptide-1 (GLP-1) agonists, the Canadian Anesthesiologists' Society has recognized that patients on GLP-1 agonists may have an increased aspiration risk due to a 'full stomach,' even after following preoperative fasting guidelines. In other words, safe fasting timelines are not known in individuals taking GLP-1 agonists, as demonstrated by recent case reports of patients who either retained or regurgitated stomach contents despite being adequately fasted.
Our primary objective is to use POCUS preoperatively to assess gastric volumes of fasted patients to demonstrate if there is a clinically significant increase in residual gastric volumes in patients on semaglutide. conditions: Pulmonary Aspiration studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 90 type: ESTIMATED name: gastric antral sonography measure: Number of participants presenting with a full stomach measure: Number of occurrences requiring change in anesthetic management plan measure: Relationship between dose, duration and timing of GLP-1 receptor agonist and gastric volume measure: Relationship between gastric emptying and purpose of GLP-1 receptor agonist administration sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: South Health Campus city: Calgary state: Alberta zip: T3M 1M4 country: Canada name: Joanna J Moser, MD, PhD role: CONTACT phone: 403-956-3883 email: joanna.moser@ahs.ca lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06263582 id: IGHID12333 briefTitle: Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-02 date: 2025-02 date: 2024-02-16 date: 2024-02-20 name: UNC Lineberger Comprehensive Cancer Center class: OTHER briefSummary: This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer treatment. A secondary objective is to investigate safety among study participants. conditions: Cervix Cancer conditions: Cervix Intraepithelial Neoplasia Grade 3 conditions: Cervix; Intraepithelial Neoplasia, Grade I conditions: Cervix; Intraepithelial Neoplasia, Grade II studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: Artesunate pessary name: blood draws for pharmacokinetics of the study drug measure: To determine the area under the plasma concentration versus time curve (AUC) of dihydroartemisinin measure: To determine the area under the plasma concentration versus time curve (AUC) of Artesunate (AS) measure: To determine the maximum concentration of Artesunate (AS) measure: To determine the maximum concentration of dihydroartemisinin (DHA) (Cmax) measure: To determine the time to maximum concentration (Tmax) of Artesunate (AS) following five consecutive days measure: To determine the time to maximum concentration (Tmax) of dihydroartemisinin (DHA measure: To determine the half-life (t1/2) of Artesunate (AS) measure: To determine the half-life (t1/2) of dihydroartemisinin (DHA) measure: To determine the apparent clearance (CL/F) of Artesunate (AS) measure: To determine the apparent clearance (CL/F) of dihydroartemisinin (DHA) measure: To determine the volume of distribution (V/F) of Artesunate (AS) measure: To determine the volume of distribution (V/F) of dihydroartemisinin (DHA) measure: Type, frequency, severity, and duration of adverse events sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lumumba Sub-County Hospital city: Kisumu country: Kenya lat: -0.10221 lon: 34.76171 hasResults: False
nctId: NCT06263569 id: SDB 2023-002 briefTitle: Effectiveness of Total Hip Arthroplasty for Patients With Osteoarthritis, a Target Trial Emulation Study acronym: EAGLE overallStatus: COMPLETED date: 2023-05-24 date: 2023-05-24 date: 2023-05-24 date: 2024-02-16 date: 2024-02-16 name: JointResearch class: OTHER briefSummary: The aim of this study is to assess the effect of total hip arthroplasty on hip disability and pain compared to non-surgery in patients with hip osteoarthritis, using target trial emulation to emulate a randomized controlled trial. conditions: Hip Osteoarthritis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 156 type: ACTUAL name: Total hip arthroplasty measure: Hip disability and Osteoarthritis Outcome Score Physical function Short form (HOOS-PS), change score from baseline measure: Numerical Rating Scale (NRS) pain during weight bearing, change score from baseline sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OLVG city: Amsterdam state: Noord Holland zip: 1090 HM country: Netherlands lat: 52.37403 lon: 4.88969 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-05-17 uploadDate: 2024-02-08T10:36 filename: Prot_SAP_000.pdf size: 949604 hasResults: False
nctId: NCT06263556 id: 2023/389 briefTitle: Effectiveness of TTNS in MS Patients With Lower Urinary Track Symptoms overallStatus: RECRUITING date: 2024-01-17 date: 2024-11-05 date: 2024-12-05 date: 2024-02-16 date: 2024-02-16 name: Bakirkoy Dr. Sadi Konuk Research and Training Hospital class: OTHER_GOV briefSummary: Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system. It is characterized with demyelinated plaques affecting subcortical, brain stem, and spinal cord nerve fibers. During the course of the disease, with the affection myelinated nerve tracks, lower urinary track symptoms may occur. 50-90% of the MS patients experience lower urinary track symptoms (LUTS) such as urinary incontinence, urgency, nocturia and/or urinary frequency during the at one point of their life.
Aim of this study is to determine the effects of transcutaneous tibial nerve stimulation (TTNS) on symptoms and quality of life in MS patients with LUTS. conditions: Multiple Sclerosis conditions: Lower Urinary Tract Symptoms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will be randomized and assigned to either group. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 64 type: ESTIMATED name: Pelvic floor exercises name: Transcutaneous posterior tibial nerve stimulation name: Sham stimulation measure: Incontinence Quality of Life (I-QOL) measure: Post-void residue (PVR) measure: Bladder diary measure: International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Bakirkoy Dr. Sadi Konuk Research and Training Hospital status: RECRUITING city: Istanbul country: Turkey name: Sibel CAGLAR role: CONTACT phone: +905333365651 email: dr.sibelcaglar@gmail.com name: Arda Can KASAP role: CONTACT phone: +905384590119 email: drardakasap@gmail.com lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06263543 id: 2023-MAH-001 briefTitle: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC acronym: SERIES overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-10 date: 2024-02-16 date: 2024-02-16 name: Reshma L. Mahtani, D.O. class: OTHER name: Gilead Sciences briefSummary: The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd. conditions: Breast Cancer conditions: Metastatic Breast Cancer conditions: Advanced Breast Cancer conditions: Hormone-receptor-positive Breast Cancer conditions: Human Epidermal Growth Factor 2 Low Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 75 type: ESTIMATED name: Sacituzumab govitecan measure: Overall response rate (ORR) measure: Clinical benefit rate (CBR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Duration of response (DOR) measure: Global Quality of Life measure: Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Laboratory and Vital Sign Abnormalities measure: Growth Factor Support sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UCLA Jonsson Comprehensive Cancer Center city: Los Angeles state: California zip: 90404 country: United States name: Aditya Bardia, M.D. role: CONTACT phone: 310-586-2093 email: ABardia@mednet.ucla.edu lat: 34.05223 lon: -118.24368 facility: Miami Cancer Institute at Baptist Health, Inc. city: Miami state: Florida zip: 33176 country: United States name: Reshma L Mahtani, D.O. role: CONTACT phone: 786-596-2000 email: rmahtani@baptisthealth.net name: Krystal Fernandez role: CONTACT phone: (786) 596-2000 email: krystal.fernandez@baptisthealth.net lat: 25.77427 lon: -80.19366 facility: Winship Cancer Institute at Emory University city: Atlanta state: Georgia zip: 30322 country: United States name: Kevin Kalinsky, M.D., M.S. role: CONTACT phone: 404-778-0519 email: kkalins@emory.edu lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06263530 id: NU22-03-00182 briefTitle: Prognostic Significance of ctDNA in HL overallStatus: RECRUITING date: 2022-01-02 date: 2023-12-31 date: 2027-12-31 date: 2024-02-16 date: 2024-02-16 name: Interni hematologicka klinika FNKV class: NETWORK name: Charles University, Czech Republic name: General University Hospital, Prague name: University Hospital Olomouc name: University Hospital Hradec Kralove name: University Hospital, Motol briefSummary: Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy. conditions: Prognostic Cancer Model studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Identification of tumor specific mutation profiles at dg. of HL based on ctDNA measure: Quantitative analysis of ctDNA level during the first-line chemotherapy measure: Identification of tumor specific mutation profiles at relapse of classical HL measure: In vitro functional characterization of identified DNA variants and/or mutations sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Hradec Kralove status: RECRUITING city: Hradec Kralove zip: 50005 country: Czechia name: Alice Sykorova, M.D., Ph.D. role: CONTACT phone: +420495 832 866 email: alice.sykorova@fnhk.cz lat: 50.20923 lon: 15.83277 facility: University Hospital Olomouc status: RECRUITING city: Olomouc zip: 77520 country: Czechia name: Vit Prochazka, prof. M.D. role: CONTACT phone: +420588 442 878 email: prochazv@fnol.cz lat: 49.59552 lon: 17.25175 facility: University Hospital Kralovske Vinohrady status: RECRUITING city: Praha zip: 10034 country: Czechia name: Heidi Mocikova, M.D., Ph.D. role: CONTACT phone: +420267163554 email: heidi.mocikova@fnkv.cz name: Katerina Klaskova, Ing. role: CONTACT phone: +420267162880 email: katerina.klaskova@fnkv.cz lat: 50.08804 lon: 14.42076 facility: Charles University status: ACTIVE_NOT_RECRUITING city: Praha zip: 12108 country: Czechia lat: 50.08804 lon: 14.42076 facility: General University Hospital status: RECRUITING city: Praha zip: 12808 country: Czechia name: Jan Koren, M.D. role: CONTACT phone: +420224962541 email: jan.koren@vfn.cz lat: 50.08804 lon: 14.42076 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-11-30 uploadDate: 2024-02-07T11:30 filename: Prot_SAP_000.pdf size: 329948 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-11-30 uploadDate: 2024-02-07T11:43 filename: ICF_001.pdf size: 82316 hasResults: False
nctId: NCT06263517 id: SPA-S-899-01-21 id: 2021-003124-33 type: EUDRACT_NUMBER briefTitle: Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients overallStatus: RECRUITING date: 2023-10-12 date: 2025-07 date: 2025-10 date: 2024-02-16 date: 2024-02-16 name: SPA Società Prodotti Antibiotici S.p.A. class: INDUSTRY name: Pharmaceutical Development and Services briefSummary: The goal of this clinical trial is to to clarify which is the best dose of administration, to select a dose and to confirm the therapeutic efficacy of clodronate in patients with painful knee osteoarthritis (OA). The clinical trial will be divided in two parts.
* in Phase III, to assess the safety and tolerability of different escalating doses of IA clodronate to confirm and extensively evaluate the therapeutic efficacy and safety of the clodronate DTD in patients with knee OA conditions: Osteoarthritis of Knee studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Randomization list will be performed with Proc Plan procedure by SAS ® Software (release 9.4 or later) software using the block randomization method with block size of 4.
Subjects eligible at Baseline will be randomly allocated to receive 2, 5, 10 /2ml or placebo according to the balanced randomization list. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 296 type: ESTIMATED name: Clodronate name: Clodronate name: Clodronate name: Placebo measure: Efficacy: VAS Reduction measure: VAS mean changes measure: VAS mean changes observed 120 minutes after IA measure: Lequesne Algofunctional Index mean changes measure: WOMAC mean changes measure: Range of motion mean changes measure: Paracetamol consumption measure: SAE Reporting measure: AE Reporting measure: Clinical signs of intolerance Recording sex: ALL minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituti Clinici Maugeri status: RECRUITING city: Castel Goffredo state: Mantova zip: 46042 country: Italy name: Lul Abdi-Ali role: CONTACT lat: 45.29403 lon: 10.473 facility: Ospedale San Pellegrino status: RECRUITING city: Castiglione delle Stiviere state: Mantova zip: 46043 country: Italy name: Paolo Roberto Ferrari role: CONTACT lat: 45.3902 lon: 10.48619 facility: Ospedale Civile Servizio di Riabilitazione Funzionale status: RECRUITING city: Volta Mantovana state: Mantova zip: 46049 country: Italy name: Luisa Selletti role: CONTACT lat: 45.32192 lon: 10.65891 facility: Azienda Ospedaliera Universitaria San Luigi Gonzaga status: NOT_YET_RECRUITING city: Orbassano state: Torino zip: 10043 country: Italy name: Filippo Castoldi role: CONTACT lat: 45.00547 lon: 7.53813 facility: Centro Riabilitativo Polifunzionale Teresio Borsalino status: RECRUITING city: Alessandria zip: 15122 country: Italy name: Marco Invernizzi role: CONTACT lat: 44.90924 lon: 8.61007 facility: IRCCS Ospedale Policlinico San Martino status: RECRUITING city: Genova zip: 16132 country: Italy name: Matteo Formica role: CONTACT lat: 44.40478 lon: 8.94438 facility: Ospedale Israelitico status: RECRUITING city: Roma zip: 00148 country: Italy name: Maria Chiara Meloni role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale San Pietro status: RECRUITING city: Rome zip: 00189 country: Italy name: Alberto Migliore role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale San Paolo status: NOT_YET_RECRUITING city: Savona zip: 17100 country: Italy name: Danilo Chiapale role: CONTACT lat: 44.30905 lon: 8.47715 facility: Azienda Ospedaliero Universitaria Senese status: RECRUITING city: Siena zip: 53100 country: Italy name: Bruno Frediani role: CONTACT lat: 43.31822 lon: 11.33064 facility: Ospedale Policlinico "G.B. Rossi" Borgo Roma status: RECRUITING city: Verona zip: 37134 country: Italy name: Luca Dalle Carbonare role: CONTACT lat: 45.4299 lon: 10.98444 hasResults: False
nctId: NCT06263504 id: DM001 briefTitle: The Influence of Complex Correction of Dental and Musculoskeletal Systems on the Frequency of Relapses of Functional Disorders in Patients With Dental Pathologies. overallStatus: NOT_YET_RECRUITING date: 2024-03-10 date: 2025-06-15 date: 2025-10-15 date: 2024-02-16 date: 2024-02-26 name: NMSI DENTMASTER class: OTHER briefSummary: In influence of complex correction of dental and musculoskeletal systems on the frequency of relapses of functional disorders in patients with somatic pathologies: a randomized pilot study there will be two groups: Group 1 (control group): Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.